1[1]Dispenzieri A,Kyle RA,Lacy MQ,et al.POEMS syndrome:definitions and long-term outcome[J].Blood,2003,101 (7):2496-2506.
2[2]Nakanishi T,Sobue I,Toyokura Y,et al.The CrowFukase syndrome:a study of 102 cases in Japan[J].Neurology,1984,34(6):712-720.
3[3]Schey S.Osteosclerotic myeloma and 'POEMS' syndrome[J].Blood Rev,1996,10(2):75-80.
4[4]Dispenzieri A.Plasma Cell Disorders:Atypical Plasma Cell Syndromes[M]//American Society of Hematology Education Program Book.Hematology.Washington DC:ASH,2005:360-367.
5[5]Gherardi RK,Belec L,Soubrier M,et al.Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome[J].Blood,1996,87 (4):1458-1465.
6[6]Watanabe O,Maruyama I,Arimura K,et al.Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome[J].Muscle Nerve,1998,21(11):1390-1397.
7[7]Michizono K,Umehara F,Hashiguchi T,et al.Circulating levels of MMP-1,-2,-3,-9,and TIMP-1 are increased in POEMS syndrome[J].Neurology,2001,56(6):807-810.
同被引文献16
1Dispenzieri A. POEMS syndrome:update on diagnosis risk - stratification and management [ J ]. Am J Hematol, 2012,87 (8) :804 - 814.
2Sekiguchi Y, Misawa S, Shibuya K, et al. Ambiguous effects of anti-VEGF monoclonal antibody (bevaeizumab) for PO- EMS syndrome [ J ]. J Neurol Neurosurg Psychiatry, 2013 March 5. doi : 10.1136/jnnp-2012 - 304874.
3Vannata B, Laurenti L, Chiusolo P, et al. Efficacy of lenalido- mide plus dexamethasone for POEMS syndrome relapsed af- ter autologous peripheral stem-cell transplantation [ J ]. Am J Hematol,2012,87 (6) : 641 - 642.
4Yamada Y, Sawai S, Misawa S, et al. Multiple angiogenetic factors are upregulated in POEMS syndrome[ J]. Ann Hema- tol,2013,92(2) :245 -248.
5Kanda T. Biology of the blood-nerve barrier and its alteration in immune mediated neuropathies [ J ]. J Neurol NeurosurgPsychiatry,2013,84 (2) :208 - 2 l 2.
6Mima A, Qi W, Hiraoka-Yamomoto J, et al. Retinal not sys- temic oxidative and inflammatory stress correlated with VEGF expression in rodent models of insulin resistance and diabetes [ J ]. Invest Ophthalmol Vis Sci, 2012,53 ( 13 ) : 8424 - 8432.
7Buxhofer-Ausch V, Gisslinger B, Stangl G, et al. Successful treatment sequence iocorporating bevaeizumab for therapy of polyneuropathy in two patients with POEMS syndrome [ J ], Leuk Res, 2012,36 ( 5 ) : e98-e100.
8Kanai K, Sawai S, Sogawa K, et al. Markedly upregulated ser- um interleukin - 12 as a novel biomarker in POEMS syn- drome [ J ]. Neurology,2012,79 (6) :575 - 582.
9Royer B, Merlusca L, Abraham J, et al, Efficacy of lenalido- mide in POEMS syndrome; A retrospective study of 20 pa- tients[ J], Am J Hematol,2013,88(3) :207 -212.
10Malkomes P, Oppermann E, Bechstein we, et al. Vascular endothelial growth factor-marker for pmllferation in thyroid diseases [ J ]. Exp Clin Endocrinol Diabetes,2013,121 ( 1 ) ~ 6.
